Englander Institute for Precision Medicine

Immunogenic Therapies Drive CAR T Cells towards Superior Efficacy.

TitleImmunogenic Therapies Drive CAR T Cells towards Superior Efficacy.
Publication TypeJournal Article
Year of Publication2021
AuthorsPetroni G, Kroemer G, Galluzzi L
JournalTrends Cancer
Volume7
Issue3
Pagination179-181
Date Published2021 Mar
ISSN2405-8025
KeywordsHumans, Neoplasms, Receptors, Chimeric Antigen, T-Lymphocytes, Tumor Microenvironment
Abstract

Autologous T cells engineered to express a chimeric antigen receptor (CAR) remain poorly effective against solid tumors, partly because solid neoplasms can establish an immunosuppressive microenvironment. Recent findings by Srivastava et al. suggest that immunogenic chemotherapeutics such as oxaliplatin can be harnessed to maximize the capacity of CAR T cells to infiltrate and control solid tumors.

DOI10.1016/j.trecan.2021.01.005
Alternate JournalTrends Cancer
PubMed ID33518493

Weill Cornell Medicine Englander Institute for Precision Medicine 413 E 69th Street
Belfer Research Building
New York, NY 10021